Related Experiment Video
Updated: Oct 9, 2025
10:20
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
25.5K
Senescence Alterations in Pulmonary Hypertension
Inés Roger1,2, Javier Milara1,2,3, Nada Belhadj2
1Centro de Investigación en Red Enfermedades Respiratorias CIBERES, Health Institute Carlos III, 28029 Valencia, Spain.
Cells
|December 24, 2021
Summary
Cellular senescence, an aging process, contributes to lung diseases like pulmonary hypertension (PH). Senescent cells in PH promote artery remodeling, offering potential targets for new senotherapy treatments.
Area of Science:
- Pulmonary Medicine
- Cellular Biology
- Aging Research
Background:
- Cellular senescence, the cessation of cell division, is linked to aging and lung diseases.
- Senescence markers are found in chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary hypertension (PH).
- Accumulated senescent cells and their secretory phenotype in aged lungs can cause persistent inflammation and tissue damage.
Purpose of the Study:
- To review the role of cellular senescence in pulmonary artery remodeling in various forms of PH.
- To analyze senescence-associated molecular pathways and cellular functions in PH.
- To discuss senotherapies as potential treatments for PH-related pulmonary artery remodeling.
Main Methods:
- Review of recent scientific literature on cellular senescence and pulmonary hypertension.
- Analysis of molecular pathways and cellular functions involved in senescence.
- Discussion of senotherapeutic strategies.
Main Results:
- Senescent cell phenotypes are present in pulmonary artery smooth muscle cells and endothelial cells of PH patients.
- These senescent cells contribute to pulmonary artery remodeling and the development of PH.
- Environmental factors like cigarette smoke and cellular stresses exacerbate senescence.
Conclusions:
- Cellular senescence plays a significant role in pulmonary artery remodeling across different PH entities.
- Understanding senescence pathways offers promising targets for developing senotherapies.
- Senotherapies may attenuate pulmonary artery remodeling and treat PH.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
317
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
317
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
238
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
238
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
271
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
271
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
277
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
277
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.3K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.3K
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
341
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
341